[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"The First Affiliated Hospital of University of Science and Technology of China\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":340},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,47,75,99,123,146,170,197,225,243,266,290,313],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":4},"100644695","endovascular-therapy-for-acute-basilar-artery-occlusion-with-large-ischemic-core-100644695",false,"NCT07672795","Endovascular Therapy for Acute Basilar Artery Occlusion With Large Ischemic Core","Efficacy and Safety of Endovascular Therapy for Acute Basilar Artery Occlusion With Large Ischemic Core: A Prospective, Multicenter, Randomized Controlled Trial","Inclusion Criteria:\n\n* Clinical symptoms or imaging findings suggestive of acute posterior circulation ischemic stroke.\n* Basilar artery occlusion confirmed by CTA, MRA, or DSA.\n* Posterior circulation ASPECTS \\\u003C7 on CT, CTA source images, or MRI-DWI.\n* Age 18 to 80 years.\n* Time from symptom onset or last known well to randomization within 24 hours.\n* Written informed consent obtained from the patient or legally authorized representative.\n* Baseline NIHSS score ≥6 before randomization.\n\nExclusion Criteria:\n\n* Pre-stroke modified Rankin Scale score ≥3.\n* Pregnancy or lactation.\n* Known allergy to contrast agents or nickel-titanium alloy.\n* Current participation in another clinical trial.\n* Systolic blood pressure \\>185 mmHg or diastolic blood pressure \\>110 mmHg that cannot be controlled with antihypertensive therapy.\n* Known hereditary or acquired bleeding diathesis, coagulation factor deficiency, or current oral anticoagulant use with INR \\>1.7.\n* Blood glucose \\\u003C50 mg\u002FdL or \\>400 mg\u002FdL, platelet count \\\u003C50 × 10\\^9\u002FL, or hematocrit \\\u003C25%.\n* Life expectancy less than 1 year.\n* Inability to complete 90-day follow-up.\n* Definite history of cerebral vasculitis.\n* Pre-existing neurological or psychiatric disorder that may interfere with neurological or functional assessment.\n* Intracranial hemorrhage on CT or MRI, except for cerebral microbleeds \\\u003C5 mm on MRI.\n* Vascular tortuosity, anatomical variation, or arterial dissection on CTA, MRA, or DSA that precludes endovascular treatment.\n* Intracranial tumor, except for small meningioma.","ALL","18 Years",{"count":19,"type":20},256,"ESTIMATED","INTERVENTIONAL",[23],"NA","Acute basilar artery occlusion is associated with high mortality and severe disability. Previous randomized trials have demonstrated the benefit of endovascular therapy in selected patients with basilar artery occlusion; however, patients with large ischemic core, commonly defined by low posterior circulation Alberta Stroke Program Early CT Score (pc-ASPECTS), remain underrepresented and the benefit-risk profile of endovascular therapy in this subgroup is uncertain.\n\nThis prospective, multicenter, randomized, open-label, blinded-endpoint trial will evaluate the efficacy and safety of endovascular therapy plus best medical management compared with best medical management alone in patients with acute basilar artery occlusion within 24 hours from symptom onset or last known well and pc-ASPECTS \\\u003C7. Eligible participants will be randomized in a 1:1 ratio to receive endovascular therapy plus best medical management or best medical management alone. The primary outcome is favorable functional outcome, defined as a modified Rankin Scale score of 0 to 3 at 90 days.",[26,27,28],"Acute Ischemic Stroke","Basilar Artery Occlusion","Large Ischemic Core",[30,31,32,33,34],"Basilar artery occlusion","Endovascular therapy","Mechanical thrombectomy","Posterior circulation stroke","Large ischemic core","NOT_YET_RECRUITING","2026-06-30",{"date":38,"type":39},"2026-07-02","ACTUAL",{"date":41,"type":20},"2026-08-01",{"date":43,"type":20},"2029-12-31",{"name":45,"class":46},"The First Affiliated Hospital of University of Science and Technology of China","OTHER",{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":21,"phases":57,"briefSummary":58,"conditions":59,"keywords":60,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},"100600228","efficacy-and-safety-of-tenecteplase-intravenous-thrombolysis-in-acute-posterior-circulation-ischemic-stroke-within-45-24-hours-after-onset-100600228","NCT07094763","Efficacy and Safety of Tenecteplase Intravenous Thrombolysis in Acute Posterior Circulation Ischemic Stroke Within 4.5-24 Hours After Onset","Efficacy and Safety of Tenecteplase Intravenous Thrombolysis in Acute Posterior Circulation Ischemic Stroke Within 4.5-24 Hours After Onset: A Multicenter, Prospective, Randomized, Open-Label, Blinded Endpoint Trial","Inclusion Criteria:\n\n1. Age ≥18 years.\n2. Meeting at least one of the following criteria: acute posterior circulation ischemic stroke confirmed by MRI; symptomatic stenosis or occlusion of a posterior circulation large vessel on vascular imaging (CTA\u002FMRA\u002FDSA); perfusion imaging demonstrating clinically relevant hypoperfusion in the posterior circulation territory.\n3. Onset time between 4.5-24 hours (for wake-up stroke or unwitnessed stroke, onset time is defined as the midpoint between last known well and symptom detection).\n4. NIHSS score\\>3.\n5. PC-ASPECTS ≥7 (if discrepancy exists between DWI and CT findings, CT assessment takes precedence).\n6. Pre-stroke mRS ≤1.\n7. Signed informed consent by the patient or legally authorized representative.\n\nExclusion Criteria:\n\n1. Contraindication to tenecteplase or its components.\n2. Planing to receive endovascular therapy with thrombectomy, angioplasty or stenting whin 3 months.\n3. Acute anterior circulation infarction confirmed by MRI, anterior circulation large vessel occlusion on vascular imaging (CTA\u002FMRA\u002FDSA), or anterior circulation hypoperfusion on perfusion imaging.\n4. History of intracranial hemorrhage.\n5. Stroke, myocardial infarction, severe traumatic brain injury, or intracranial\u002Fspinal surgery within the preceding 3 months.\n6. Intracranial tumor, arteriovenous malformation (AVM), or giant aneurysm.\n7. Active internal bleeding, major surgery, trauma, gastrointestinal\u002Furinary tract bleeding within 3 weeks.\n8. Non-compressible arterial puncture within 1 week.\n9. Suspected aortic dissection.\n10. Clinically significant bleeding or coagulopathy, including: Warfarin use with INR \\>1.7 or PT \\>15 s; Low-molecular-weight heparin within 24 hours; Direct oral anticoagulants within 48 hours; Laboratory abnormalities (e.g., APTT \\>40 s).\n11. Platelet dysfunction or platelet count \\\u003C100×10⁹\u002FL.\n12. Uncontrolled hypertension (systolic BP \\>180 mmHg or diastolic BP \\>110 mmHg unresponsive to antihypertensive therapy).\n13. Uncontrolled hypoglycemia\u002Fhyperglycemia (\\\u003C50 mg\u002FdL \\[2.8 mmol\u002FL\\] or \\>400 mg\u002FdL \\[22.2 mmol\u002FL\\]).\n14. Pregnancy or lactation.\n15. A life expectancy of less than three months.\n16. Participation in other clinical trials within 3 months or ongoing trial enrollment.\n17. Inability to follow up (e.g., no fixed residence, overseas patients).\n18. Patient deemed unsuitable for the trial by site investigator.","100 Years",{"count":56,"type":20},406,[23],"This study aims to evaluate the efficacy and safety of tenecteplase (TNK) intravenous thrombolysis within the extended time window (4.5 to 24 hours) in patients with acute posterior circulation ischemic stroke.",[26],[61,62,63,64],"TNK Intravenous Thrombolysis","Acute ischemic stroke","posterior circulation","Beyond optimal time window","RECRUITING","2026-06-05",{"date":68,"type":39},"2026-06-08",{"date":70,"type":39},"2025-11-05",{"date":72,"type":20},"2027-12-30",{"name":45,"class":46},1,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":21,"phases":84,"briefSummary":86,"conditions":87,"keywords":90,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":98,"locationsCount":74},"100502806","phase-3-endovascular-thrombectomy-alone-versus-intravenous-thrombolysis-plus-thrombectomy-on-acute-basilar-artery-occlusion-100502806","NCT05827042","Endovascular Thrombectomy Alone Versus Intravenous Thrombolysis Plus Thrombectomy on Acute Basilar Artery Occlusion","Endovascular Thrombectomy Alone Versus Intravenous Thrombolysis Plus Endovascular Thrombectomy on Acute Basilar Artery Occlusion - a Multicenter, Randomized Controlled, Clinical Trial","Inclusion Criteria:\n\n1. Patients presenting with posterior circulation ischemic stroke symptoms due to basilar artery occlusion or vertebral artery occlusions that prevent antegrade flow into the basilar artery;\n2. Time from stroke onset to randomization within 4.5 hours of estimated time of basilar artery occlusion;\n3. Patient's age ≥ 18 years;\n4. Presence of basilar artery or vertebral artery occlusion, confirmed by CT Angiography (CTA), MR Angiography (MRA) or Digital Subtraction Angiography (DSA). In case of vertebral artery occlusion, the occlusion must completely prevent antegrade flow into the basilar artery;\n5. Patients presenting with acute ischemic stroke eligible to receive both endovascular thrombectomy and intravenous thrombolysis using standard criteria;\n6. Baseline National Institutes of Health Stroke Scale (NIHSS) score ≥ 10;\n7. The patient or patient's legal representative signs the informed consent form.\n\nExclusion Criteria:\n\n1. CT or MR evidence of intracerebral hemorrhage (the presence of \\\u003C 10 microbleeds is allowed);\n2. Pre-stroke modified Rankin scale (mRS) score ≥ 2;\n3. Posterior circulation Acute Stroke Prognosis Early CT Score (PC-ASPECTS) on CT\u002F CTA-Source Images\\\u003C6; PC-ASPECTS on magnetic resonance imaging-diffusion weighted imaging (MRI-DWI) \\\u003C5;\n4. Pregnant or lactating women;\n5. Allergy to contrast agent or nitinol alloy;\n6. Life expectancy\\\u003C1 year;\n7. CTA\u002FMRA\u002FDSA show vascular tortuosity, anatomical variation or artery dissection, which would make it difficult to perform endovascular treatment;\n8. Participating in other clinical trials;\n9. Systolic blood pressure \\>185 mmHg or diastolic blood pressure \\>110 mmHg, which can not be controlled by antihypertensive drugs;\n10. Genetic or acquired hemorrhagic diathesis, lack of anticoagulant factor; oral anticoagulant with international normalized ratio (INR) \\> 1.7; or novel oral anticoagulant within prior 48 hours;\n11. Blood glucose \\\u003C50 mg\u002Fdl (2.8 mmol\u002FL) or \\>400 mg\u002Fdl (22.2 mmol\u002FL), platelet\\\u003C 100\\*109\u002FL;\n12. Renal insufficiency defined as serum creatinine \\>2.0 mg\u002Fdl (or 176.8 μ mol\u002Fl), glomerular filtration rate \\\u003C30 mL\u002Fmin, need for hemodialysis or peritoneal dialysis;\n13. Patients who cannot complete 90-day follow-up (such as patients without fixed residence, overseas patients, etc);\n14. The patient has acute ischemic cerebral infarction within 3 months from randomization;\n15. The patient had a history of or clinical suspicion for cerebral vasculitis or infectious endocarditis;\n16. The patient has nervous system disease or mental disorder before stroke onset, which may affect the assessment of their condition;\n17. CT or MR examination showed large cerebellar infarction with obvious space occupying effect and compression of the fourth ventricle;\n18. Patients with extensive bilateral thalamic or extensive bilateral brainstem infarction on CT or MR examination;\n19. CTA\u002FMRA\u002FDSA show both anterior and posterior circulation large vessel occlusion;\n20. Patients with intracranial tumors (except small meningiomas);\n21. Patients who received intravenous thrombolytics treatment before the randomization.",{"count":83,"type":20},338,[85],"PHASE3","To assess the effect of endovascular thrombectomy alone compared to intravenous thrombolysis plus endovascular thrombectomy in acute basilar artery occlusion patients within 4.5 hours from onset on efficacy and safety outcomes.",[27,88,89],"Acute Cerebrovascular Accident","Stroke Due to Basilar Artery Occlusion",[91,92],"Thrombectomy","thrombolysis",{"date":94,"type":39},"2026-06-09",{"date":96,"type":39},"2023-05-09",{"date":36,"type":20},{"name":45,"class":46},{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":21,"phases":108,"briefSummary":110,"conditions":111,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":74},"100627536","phase-2-safety-and-efficacy-of-baricitinib-after-endovascular-treatment-in-acute-anterior-circulation-large-vessel-occlusion-a-multicenter-randomized-controlled-clinical-trial-100627536","NCT07449910","Safety and Efficacy of Baricitinib After Endovascular Treatment in Acute Anterior Circulation Large Vessel Occlusion: A Multicenter, Randomized Controlled Clinical Trial","Safety and Efficacy of Baricitinib Combined With Acute Large Vessel Occlusion Recanalization : A Multicenter, Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n1. Age is 18 years old or above.\n2. Diagnosed as anterior circulation large vessel occlusion stroke by CTA, MRA or DSA.\n3. Randomized within 24h after the onset.\n4. The NIHSS score is above 5 and the ASPECT score is above 3 points while receiving imaging examination;\n5. The mTICI score after endovascular treatment (EVT) is above 2b.\n6. informed consent.\n\nExclusion Criteria:\n\n1. Intracranial hemorrhage confirmed by CT or MRI.\n2. mRS score\\>2 for patients \\\u003C80 years, or mRS score\\>1 for those ≥80 years before onset.\n3. Pregnant or lactating women.\n4. Allergic to contrast agents.\n5. Allergic to baricitinib or having contraindications for using baricitinib.\n6. Participating in other clinical studies.\n7. Systolic blood pressure \\>185 mmHg or diastolic blood pressure \\>110 mmHg, and unable to be controlled by oral antihypertensive drugs.\n8. Genetic or acquired bleeding diathesis, lack of anticoagulant factors or having taken oral anticoagulants and INR \\>1.7.\n9. Hemoglobin value \\\u003C8g\u002FL.\n10. Recent history of using other JAK inhibitors or potent immunosuppressants, including but not limited to the combined use with potent immunosuppressive drugs such as azathioprine, tacrolimus, tofacitinib and fedratinib, etc. Tortuous arteries make the thrombectomy device unable to reach the target blood vessel.\n11. Previous history of diagnosed viral hepatitis and tuberculosis.",{"count":107,"type":20},750,[109,85],"PHASE2","The primary purpose of this study is to evaluate the efficacy and safety of Baricitinib combined with endovascular therapy in patients with acute anterior circulation large vessel occlusion, to address futile recanalization with priority, and to elucidating the mechanism of JAK\u002FSTAT pathway inhibition on neuroprotection and inflammatory regulation.",[112,113,114],"Acute Ichemic Stroke","Anterior Cerebral Artery Stroke","Baricitinib","2026-02-27",{"date":117,"type":39},"2026-03-04",{"date":119,"type":20},"2026-03-17",{"date":121,"type":20},"2028-01-31",{"name":45,"class":46},{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":129,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":131,"enrollmentInfo":132,"targetDuration":4,"studyType":21,"phases":134,"briefSummary":135,"conditions":136,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":4},"100609404","phase-2-total-neoadjuvant-therapy-with-pd-1-for-locally-advcancer-rectal-cancer-100609404","NCT07214142","Total Neoadjuvant Therapy With PD-1 for Locally Advcancer Rectal Cancer","Efficacy and Safety of Total Neoadjuvant Chemoradiotherapy Combined With PD-1 Therapy for Locally Advanced Rectal Cancer With High Risk of Recurrence","TNT-Immunity","Inclusion Criteria:\n\n1. Pathologically confirmed rectal adenocarcinoma;\n2. Mid-low rectal cancer, with the lower edge of the tumor located within 12 cm from the anal verge;\n3. Magnetic resonance imaging (MRI) suggests locally advanced rectal cancer (T3 or T4 and M0), accompanied by at least one of the following risk factors: cT4, N2, lymphovascular invasion, involvement of the mesorectal fascia, or enlarged lateral lymph nodes (short-axis diameter \\> 8 mm); patients with potentially resectable disease;\n4. Polymerase chain reaction (PCR) testing indicates microsatellite stability (MSS) type;\n5. No prior antitumor therapy, such as chemotherapy, radiotherapy, immunotherapy, or targeted therapy;\n6. Age between 18 and 75 years;\n7. ECOG Performance Status (PS) score of 0-1;\n8. Laboratory test results: WBC ≥ 3.5 × 10\\^9\u002FL, Hb ≥ 100 g\u002FL, PLT ≥ 100 × 10\\^9\u002FL; normal liver and kidney function;\n9. Absence of severe comorbidities, and ability to tolerate surgical treatment;\n10. The patient or their immediate family member voluntarily agrees to participate in this study and provides written informed consent.\n\nExclusion Criteria:\n\n1. Recurrent rectal cancer;\n2. Synchronous colorectal cancer;\n3. Pregnant or lactating patients;\n4. History of other malignant tumors;\n5. Previous antitumor therapy, including chemotherapy or radiotherapy;\n6. Dysfunction of vital organs such as cardiac or pulmonary insufficiency;\n7. History of autoimmune diseases or immunodeficiency disorders;\n8. Use of immunosuppressive drugs within the past year;\n9. Distant metastasis to organs such as the abdominal cavity, pelvis, liver, or lungs;\n10. Active bleeding;\n11. Tumor involvement of adjacent structures such as the prostate or sacral organs, making the tumor unresectable;\n12. Allergy to chemotherapeutic agents, immune checkpoint inhibitors, or cetuximab;\n13. Psychiatric disorders or lack of capacity for civil conduct, unable to provide informed consent.","75 Years",{"count":133,"type":20},30,[109],"Research Objective:To investigate the efficacy and safety of the \"total neoadjuvant chemoradiotherapy combined with immunotherapy\" regimen for the treatment of locally advanced rectal cancer with high-risk features for recurrence.\n\nStudy Design:A single-arm, multicenter clinical study.\n\nStudy Population: Patients with locally advanced rectal cancer presenting with high-risk features for local recurrence.",[137],"Rectal Cancer Patients","2025-10-08",{"date":140,"type":39},"2025-10-09",{"date":142,"type":20},"2025-10-01",{"date":144,"type":20},"2030-12-31",{"name":45,"class":46},{"id":147,"slug":148,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":152,"eligibilityCriteria":153,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":154,"targetDuration":4,"studyType":21,"phases":156,"briefSummary":157,"conditions":158,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":74},"100605880","phase-3-tenecteplase-vs-medical-management-in-45-24h-lvo-no-access-to-evt-100605880","NCT07168278","Tenecteplase vs Medical Management in 4.5-24h LVO no Access to EVT","Tenecteplase vs Medical Management in 4.5-24h Anterior Circulation Large Vessel Occlusion With no Access to EVT","TNK LATE","Inclusion Criteria:\n\n* Age 18 years or greater\n* Acute ischemic stroke presenting in the 4.5 to 24 hour window from last seen well (including wake-up stroke and no witness stroke).\n* Prestroke mRS 0-2\n* NIHSS 6 to 25\n* Aspect ≥ 7\n* ICA terminus, M1, dominant M2 occlusion on CTA or MRA\n* Clinical-imaging mismatch assessed by investigator\n* Patients with no access to EVT at the time of randomization\n\nExclusion Criteria:\n\n* Current or past history of significant bleeding over the past 6 months;\n* History of intracranial hemorrhage (including possible subarachnoid hemorrhage or subarachnoid hemorrhage due to an aneurysm) or evidence or suspected intracranial hemorrhage;\n* Known bleeding tendency;\n* Recent severe or dangerous bleeding, or active ulcerative gastrointestinal disease;\n* History of central nervous system injury (e.g., intracranial tumor, aneurysm, or arteriovenous malformation, intracranial or spinal surgery), or recent head injury；\n* Tumors that increase risk of bleeding;\n* Severe liver dysfunction, including liver failure, cirrhosis, portal hypertension (esophageal varices), and active hepatitis;\n* Know arterial \u002F venous malformation or aneurysm;\n* Bacterial endocarditis, pericarditis, or acute pancreatitis;\n* Patients receiving effective anticoagulant therapy (vitamin K antagonists with INR \\> 1.3, or other oral anticoagulants exceeding the upper limit of the corresponding standard range);\n* Heparin use within the past 48 hours and prothrombin time exceeding the upper limit of the standard range;\n* Over the past 3 months, undergone major surgery, organ biopsy, or suffered a serious injury;\n* Over the past 2 weeks, receiving prolonged ( \\>2 minutes) cardiopulmonary resuscitation, childbirth, or non-stressful vascular puncture (such as subclavian or jugular vein puncture);\n* Stroke episode occurred with epileptic seizure;\n* History of stroke comorbid with diabetes;\n* History of stroke over the past 3 months；\n* Acute bleeding tendency, including platelet count below 100×10⁹\u002FL or other conditions;\n* SBP \\>185 mmHg or DBP \\>110 mmHg, or requiring intensive treatment (intravenous antihypertensive drugs) to lower blood pressure to within limits;\n* Blood glucose \\\u003C2.8 mmol\u002FL or \\>22.2 mmol\u002FL (\\\u003C50 mg\u002FdL or \\>400 mg\u002FdL)；\n* Patient life expectancy of less than 1 year;\n* Simultaneous occlusion of multiple blood vessels, defined as bilateral MCAs or MCAs combined with the basilar artery;\n* Pregnant women or nursing mothers；\n* Patients with a low likelihood of 3-month follow-up；\n* Over the past 3 months participated in other interventional clinical trials.",{"count":155,"type":20},794,[85],"The goal of this clinical trial is to learn if tenectplase works to acute ischemic stroke (AIS) with onset 4.5-9 hours. It will also learn about the safety of tenectplase in AIS with onset 4.5-9 hours. The main question it aims to answer is: Does tenectplase improve the 90-days functional outcome in participants with acute large vessel occlusion? Researchers will compare tenectplase thrombolysis to non-use to see if tenectplase works to improve the functional outcome in participants with onset 4.5-9 hours. Participants will:\\* Receive 0.25mg\u002Fkg (max 25mg) tenectplase at admission (after randomization) .\\* Receive neurological assessment at admission, Day 5-7 or on hospital discharge (whichever earlier). Audio or video of the assessment may be recorded if possible.\\* Receive brain CT + CT angiogram + CT perfusion and MRI after randomization, where the CT scan may be repetitive.",[26,159,160,161],"Large Vessel Occlusion","Tenecteplase","Thrombolysis","2025-09-05",{"date":164,"type":39},"2025-09-11",{"date":166,"type":20},"2025-11-01",{"date":168,"type":20},"2028-05-31",{"name":45,"class":46},{"id":171,"slug":172,"hasResults":11,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":176,"eligibilityCriteria":177,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":178,"targetDuration":4,"studyType":21,"phases":180,"briefSummary":181,"conditions":182,"keywords":184,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":74},"100554756","an-exploratory-clinical-study-of-scar02-targeting-bcma-and-cd19-for-the-treatment-of-refractory-autoimmune-diseases-100554756","NCT06503224","An Exploratory Clinical Study of SCAR02 Targeting BCMA and CD19 for the Treatment of Refractory Autoimmune Diseases","An Exploratory Clinical Study of a Fourth-generation Autologous CAR-T Cell Injection (SCAR02) Targeting BCMA and CD19 for the Treatment of Refractory Autoimmune Diseases","SCAR02","Inclusion Criteria:\n\n1. Sign the informed consent form.\n2. At the time of signing the informed consent form, the age of 18 years old or above, both male and female.\n3. Bone marrow hematopoietic function is satisfied: white blood cell count ≥3×10\\^9\u002FL; neutrophil count ≥1×10\\^9\u002FL (not receiving colony-stimulating factor within 2 weeks prior to screening); hemoglobin ≥60g\u002FL.\n4. Liver function fulfillment: ALT≤3×ULN; AST≤3×ULN; TBIL≤3×ULN.\n5. Renal function fulfillment: creatinine clearance CrCl ≥ 60mL\u002Fmin.\n6. Coagulation function meets: international standard ratio INR \\\u003C1.5 times ULN, prothrombin time PT \\\u003C1.5 times ULN.\n\nPatients with rheumatoid arthritis must also meet the following enrollment criteria:\n\n1. Diagnosis of rheumatoid arthritis according to the 2010 ACR \u002F EULAR diagnostic criteria.\n2. Fulfillment of one of the following conditions: DAS28-ESR \\>3.2 or CDAI \\>10 at 3 months after use of a standard treatment regimen prior to screening; inability to taper hormones (prednisone) to less than 7.5 mg\u002Fday; and number of swollen joints and\u002For number of joints with tenderness ≥3. Standard treatment regimen is defined as the stable use of any of the following (alone or in combination): corticosteroids, nonsteroidal anti-inflammatory drugs ( NSAIDs) and csDMARDs, including methotrexate, leflunomide, hydroxychloroquine, salazosulfapyridine, elamodex, tretinoin, and paeonia lactiflora total, as well as biological agents (including TNF inhibitors, non-TNF inhibitors, and JAK inhibitors).\n3. Stable treatment with 1 or 2 cs DMARD(s) prior to enrollment as follows: at least 12 weeks of methotrexate and at least 4 weeks of administration at a dose of 7.5-25 mg\u002Fweek; at least 4 weeks of stable hydroxychloroquine doses of ≤400 mg\u002Fd; at least 4 weeks of stable oral salicylazosulfapyridine 1 to 3 g\u002Fd; at least 4 weeks of stable oral leflunomide 10-20 mg \u002Fd.\n\nPatients with SLE will also be required to meet the following enrollment criteria:\n\n1. Diagnosis of SLE according to the 2019 EULAR\u002FACR classification criteria for SLE.\n2. A history of SLE for at least 6 months prior to screening, with the disease remaining active 2 months after the use of a standard treatment regimen prior to screening. Standard treatment regimen is defined as stable use of any of the following (alone or in combination): corticosteroids, antimalarials, nonsteroidal anti-inflammatory drugs (NSAIDs), and other immunosuppressive or biologic agents, including azathioprine, mertiomaxolide, cyclophosphamide, methotrexate, leflunomide, tacrolimus, cyclosporine, belimumab, rituximab, and tetracycline.\n3. BILAG-2004 assessment of the presence of at least 1 grade A or 2 grade B organ scores.\n4. Positive for at least one of the following antibodies: anti-nuclear antibody, anti-ds-DNA antibody, anti-Sm antibody.\n5. SLEDAI-2000 score ≥ 8 during the screening period.\n\nPatients with dry syndrome were also required to meet the following enrollment criteria:\n\n1. Diagnosis of dry syndrome according to the 2002 International Classification Criteria for Primary Dry Syndrome or the 2016 ACR\u002FEULAR classification criteria.\n2. Diagnosis of pSS-TP with platelet count \\\u003C30 x 10\\^9\u002FL.\n3. History of dry syndrome for at least 6 months prior to screening and disease still active 2 months after use of conventional treatment regimen prior to screening. Definition of conventional therapy:Use of glucocorticoids (above 1 mg\u002FKg\u002Fd) and cyclophosphamide, and any of the following immunomodulatory drugs for more than 6 months: antimalarials, azathioprine, mycophenolate mofetil, methotrexate, leflunomide, tacrolimus, and cyclosporine, as well as biologics, such as rituximab, belimumab, and tetraciprazole.\n\nPatients with systemic sclerosis were also required to meet the following enrollment criteria:\n\n1. Diagnosis of systemic sclerosis according to the 2013 ACR classification criteria for systemic sclerosis.\n2. Positive antinuclear antibodies at screening.\n3. Presence of clear evidence of HRCT progression.\n4. History of systemic sclerosis for at least 6 months prior to screening, and active disease 2 months after use of a conventional treatment regimen prior to screening. Definition of conventional therapy:Use of glucocorticoids (above 0.5 mg\u002FKg\u002Fd) and cyclophosphamide for more than 6 months, as well as any of the following immunomodulatory medications: antimalarials, azathioprine, mycophenolate mofetil, methotrexate, leflunomide, tacrolimus, and cyclosporine, as well as biologics, such as rituximab and belimumab.\n\nExclusion Criteria:\n\n1. pre-screening presence of clinically significant CNS disease or pathological changes not caused by the disease itself, including, but not limited to: stroke, apoplexy, aneurysm, epilepsy, convulsions, aphasia, severe craniocerebral injury, dementia, Parkinson's disease, cerebellar disorders, organic brain syndromes, or insanity.\n2. Those suffering from relatively serious heart diseases such as angina pectoris, myocardial infarction, heart failure and arrhythmia.\n3. History of major organ transplantation or hematopoietic stem cell\u002Fbone marrow transplantation.\n4. vaccination, B-cell targeted therapy within 4 weeks prior to screening.\n5. History of any malignant disease.\n6. Patients with end-stage renal failure.\n7. Presence or suspected presence of uncontrolled fungal, bacterial, viral or other infections.\n8. History of severe allergy to drugs used in clinical studies or raw materials of test drugs, such as cyclophosphamide, fludarabine, DMSO.\n9. The patient is positive for HBV surface antigen, or HBV core antibody and positive for DNA by RT-PCR; positive for HCV antibody or positive for HIV antibody or positive for syphilis or positive for CMV DNA or positive for EBV DNA.\n10. Females who are pregnant or breastfeeding or who plan to have a pregnancy within 2 years of return infusion of the test drug; partners of male patients who plan to become pregnant within 2 years of treatment with the test drug.\n11. Evidence of active tuberculosis infection.\n12. other circumstances assessed by the investigator as unsuitable for enrollment.",{"count":179,"type":20},18,[23],"This is an open label, single-site, dose-escalation study in up to 18 participants with refractory autoimmune diseases. This study aims to evaluate the safety and efficacy of the treatment with Anti-BCMA and CD19 CART",[183],"Autoimmune Diseases",[185,186,187,188],"rheumatoid arthritis","systemic lupus erythematosus","dry syndrome","systemic sclerosis","2025-04-21",{"date":191,"type":39},"2025-04-24",{"date":193,"type":39},"2024-04-09",{"date":195,"type":20},"2028-04-30",{"name":45,"class":46},{"id":198,"slug":199,"hasResults":11,"nctId":200,"briefTitle":201,"officialTitle":202,"acronym":4,"eligibilityCriteria":203,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":204,"enrollmentInfo":205,"targetDuration":4,"studyType":21,"phases":207,"briefSummary":208,"conditions":209,"keywords":211,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":74},"100581903","clinical-efficacy-and-safety-of-robot-assisted-total-knee-arthroplasty-100581903","NCT06856356","Clinical Efficacy and Safety of Robot-assisted Total Knee Arthroplasty","Comparison of Clinical Efficacy and Safety of Robot-assisted Total Knee Arthroplasty and Conventional Total Knee Arthroplasty: a Randomized Controlled Study","Inclusion Criteria:\n\n1. Subjects voluntarily participate in the trial and sign the informed consent form;\n2. Aged 18 to 80 years old (inclusive), regardless of gender;\n3. Patients who need total knee replacement surgery;\n4. Those who can communicate well with the researchers and comply with the trial requirements.\n\nExclusion Criteria:\n\n1. Patients who are allergic to the drugs used in this trial or the implant materials;\n2. Patients with immature bone development;\n3. Patients with active infection;\n4. Patients with neuropathy of the knee joint;\n5. Patients with poor bone quality that is not conducive to prosthesis fixation;\n6. Patients with general conditions or concomitant diseases that make it difficult for people to tolerate surgery;\n7. Patients with insufficient quadriceps muscle strength;\n8. Patients with insufficient skin coverage near the surgical site and intolerance to surgery;\n9. Patients with severe femoral or tibial deformities and other severe deformities outside the joint;\n10. Patients with metal implants in the joint surgical area that affect the execution of the surgical plan;\n11. Pregnant or lactating women;\n12. Patients with severe epilepsy or mental illness;\n13. Patients with alcohol dependence or drug addiction;\n14. Patients with severe coagulation disorders;\n15. Patients who have participated in or are participating in other clinical trials within one month of enrollment;\n16. Patients who are considered by the researchers to be unsuitable for participating in this clinical trial for other reasons. Those who meet any of the above exclusion criteria need to be excluded.","80 Years",{"count":206,"type":20},40,[23],"The purpose of this clinical trial is to understand the application value of the Orthopedic Joint Surgery Navigation System in assisting surgeons to accurately place prosthetic components in adult knee replacement surgery. It will also confirm its effectiveness and safety in clinical application.",[210],"Osteoarthritis, Knee",[212,213,214,215,216],"total knee arthroplasty","robot-assisted","alignment","satisfication","complication","2025-02-26",{"date":219,"type":39},"2025-03-04",{"date":221,"type":39},"2023-04-01",{"date":223,"type":20},"2026-12-31",{"name":45,"class":46},{"id":226,"slug":227,"hasResults":11,"nctId":228,"briefTitle":229,"officialTitle":229,"acronym":4,"eligibilityCriteria":230,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":231,"targetDuration":4,"studyType":21,"phases":232,"briefSummary":233,"conditions":234,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":236,"startDateStruct":238,"completionDateStruct":240,"leadSponsor":242,"locationsCount":74},"100554757","safety-and-efficacy-of-swk002-in-patients-with-d2t-rheumatoid-arthritis-100554757","NCT06503237","Safety and Efficacy of SWK002 in Patients With D2T-Rheumatoid Arthritis","Inclusion Criteria:\n\n1. no gender restriction and age of 18 years and above at the time of signing the informed consent form.\n2. written informed consent approved by the Ethics Committee must be signed in person by all subjects or guardians prior to the commencement of any screening procedure.\n3. adult refractory patients who meet the 2010 ACR \u002F EULAR RA diagnostic criteria, with refractory defined as (1) failure of treatment with csDMARDs (2) experiencing failure of treatment with ≥2 bDMARDs\u002FtsDMARDs with different mechanisms of action (3) meeting one of the following criteria: 1) DAS28-ESR \\>3.2 or CDAI \\>10 2) inability to hormone Hormone cannot be reduced to less than 7.5mg\u002Fday (3) Number of swollen joints and\u002For painful joints ≥3.\n4. Stable treatment with 1 or 2 cs DMARD ( s ) prior to enrollment as follows: (1) at least 12 weeks of methotrexate and at least 4 weeks of administration at a dose of 7.5-25 mg\u002Fweek (2) at least 4 weeks of stable hydroxychloroquine dose of ≤400 mg\u002Fd (3) at least 4 weeks of stable oral salicylsulphadiazepine 1-3 g\u002Fd (4) at least 4 weeks of stable oral leflunomide 10-20 mg\u002Fday Methylphenidate 10-20 mg\u002Fd.\n5. no active or latent tuberculosis.\n6. Adequate organ function: (1) blood creatinine ≤1.5 times the upper limit of normal, or glomerular filtration rate (eGFR) ≥60m\u002Fmin\u002F1.73m2 as estimated by the MDRD formula (2) and ALT ≤ 5 times the upper limit of normal for the corresponding age and total bilirubin ≤ 2.0 mg\u002Fdl (3) and ≤ 1 grade of dyspnea and oxygen saturation \\> 91% in room air.\n7. hemodynamically stable with a left ventricular ejection fraction (LVEF) ≥45% as determined by echocardiography or multichannel radionuclide angiography (MUGA).\n8. female subjects of childbearing potential and all male subjects must agree to use a highly effective method of contraception until at least 12 months after SWK002 infusion and until two consecutive PCR assays show no more CAR-T cells in the body.\n\nExclusion Criteria:\n\n1. malignant tumors.\n2. subjects with current or history of CNS disorders such as seizures, cerebrovascular ischemia\u002Fhemorrhage, dementia, cerebellar disease, or any autoimmune disease with CNS involvement.\n3. previous subjects who have undergone allogeneic hematopoietic stem cell transplantation (HSCT).\n4. subjects who have received chemotherapy other than pretreatment chemotherapy within 2 weeks prior to infusion.\n5. subjects who have received other investigational drug therapy within 30 days prior to signing the informed consent.\n6. active hepatitis B (defined as hepatitis B surface antigen positivity or hepatitis B core antibody positivity combined with a hepatitis B virus DNA test value \\>1000 copies\u002Fml) or hepatitis C (HCV RNA positivity) subjects.\n7. HIV antibody positive or syphilis spirochete antibody positive subjects.\n8. subjects with uncontrolled acute life-threatening bacterial, viral or fungal infections (e.g., positive blood cultures ≤ 72 hours prior to infusion).\n9. subjects who have lost or donated more than 400 mL of blood within 2 months prior to screening or have received a blood transfusion.\n10. any history of definite drug or food allergy, especially to drugs related to the therapeutic agents (e.g., fludarabine, cyclophosphamide) or product components (e.g., DMSO) used in this trial.\n11. any systemic cytotoxic or systemic immunosuppressive agent within 6 months prior to screening or during the study period, or any localized cytotoxic or localized immunosuppressive agent within 30 days or 5 half-lives (whichever is longer) prior to screening or during the study period.\n12. pregnancy (as determined by blood pregnancy test) or lactation.\n13. prevalence of systemic inflammatory diseases other than RA (except secondary Sjogren\\'s syndrome), including but not limited to juvenile chronic arthritis, Crohn\\'s disease, ulcerative colitis, psoriatic arthritis, systemic lupus erythematosus, ankylosing spondylitis, reactive arthropathy, systemic vasculitis, or gout.\n14. the existence of unstable angina pectoris and\u002For myocardial infarction in the 6 months prior to signing the informed consent.\n15. other conditions that, in the opinion of the investigator, should not be enrolled in this clinical study, such as poor compliance.",{"count":179,"type":20},[23],"This is an open label, single-site, dose-escalation study in up to 18 participants with refractory rheumatoid arthritis. This study aims to evaluate the safety and efficacy of the treatment with Anti-CD19 CART.",[235],"Rheumatoid Arthritis",{"date":237,"type":39},"2025-02-28",{"date":239,"type":39},"2023-11-09",{"date":241,"type":20},"2026-03",{"name":45,"class":46},{"id":244,"slug":245,"hasResults":11,"nctId":246,"briefTitle":247,"officialTitle":247,"acronym":4,"eligibilityCriteria":248,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":249,"targetDuration":4,"studyType":21,"phases":251,"briefSummary":252,"conditions":253,"keywords":255,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":258,"lastUpdatePostDateStruct":259,"startDateStruct":261,"completionDateStruct":263,"leadSponsor":265,"locationsCount":74},"100559080","a-multicenter-randomized-controlled-clinical-investigation-to-evaluate-the-safety-and-effectiveness-of-the-super-bore-87f-aspiration-catheters-in-the-treatment-of-acute-intracranial-large-vessel-occlusion-100559080","NCT06559475","A Multicenter, Randomized Controlled Clinical Investigation to Evaluate the Safety and Effectiveness of the Super-Bore 8\u002F7F Aspiration Catheters in the Treatment of Acute Intracranial Large Vessel Occlusion","Inclusion Criteria:\n\n1. Aged 18 years or older;\n2. Clinical presentation consistent with acute ischemic stroke (AIS);\n3. Able to receive mechanical thrombectomy within 24 hours of onset;\n4. Pre-morbid mRS score of 0 or 1;\n5. Baseline NIHSS score of 6 or greater;\n6. Complete or near-complete occlusion (eTICI 0-1) of the intracranial segment of the internal carotid artery (ICA), the M1 segment of the middle cerebral artery (MCA), or the basilar artery (with or without involvement of the intracranial vertebral artery) confirmed by angiography who can undergo intravascular thrombectomy;\n7. Vessel diameter ≥2.2 mm at the occlusion site;\n8. ASPECTS or PC-ASPECTS score of 6-10 on NCCT, CTA-source imaging, or DWI-MRI;\n9. Written informed consent obtained from the patient or the patient's qualified representative.\n\nExclusion Criteria:\n\n1. Pregnant or lactating women;\n2. Severe allergic reactions to contrast agents;\n3. Current participation in other clinical studies;\n4. Known hereditary or acquired bleeding disorders, platelet count \\\u003C50,000\u002FµL, or coagulation factor deficiencies;\n5. Renal failure with serum creatinine ≥3 mg\u002FdL or Glomerular Filtration Rate (GFR) \\\u003C30 mL\u002Fmin;\n6. Expected survival \\\u003C 6 months or known cancer with metastases;\n7. Clinical manifestations suggesting subarachnoid hemorrhage, despite normal CT or MRI findings;\n8. Suspected aortic dissection;\n9. Known arterial condition in a proximal vessel that requires treatment or prevents access to the site of occlusion or safe recovery of the investigational device (for example, severe stenosis, complete occlusion in the cervical ICA, tandem occlusion);\n10. High degree of suspicion of intracranial arterial disease (ICAD), such as evidence of multifocal ICAD on CTA, MRA, or DSA, or any other finding that is highly suggestive of ICAD as the underlying etiology of the occlusion;\n11. Evidence of dissection in the extracranial or intracranial cerebral arteries;\n12. Intracranial hemorrhage on CT or MRI;\n13. Evidence of intracranial mass effect or tumor (except small meningiomas defined as ≤ 3cm and asymptomatic)) on CT or MRI;\n14. Suspicious of cerebral vasculitis or infectious endocarditis;\n15. Pre-existing neurological or psychiatric disease that would confound the neurological or functional evaluation, e.g., dementia with prescribed anti-cholinesterase inhibitor;\n16. Clinical history, past imaging or clinical judgement suggest that the intracranial occlusion is chronic;\n17. Excessive vascular access tortuosity or target vessel size that will likely prevent endovascular access with the Super-Bore Aspiration Catheters;\n18. Intracranial stent implanted in the same vascular territory that would preclude the safe deployment\u002Fremoval of the thrombectomy devices;\n19. Occlusions in multiple vascular territories (e.g., bilateral anterior circulation, or anterior circulation\u002Fvertebrobasilar system) as confirmed on CTA\u002FMRA, or clinical evidence of bilateral strokes or strokes in multiple territories as determined by the treating physician;\n20. Known aneurysm at or near the target treatment segment;\n21. Known glucose level\\\u003C 50 mg\u002Fdl (2.78 mmol\u002FL) or \\> 400 mg\u002Fdl (22.20 mmol\u002FL)；\n22. Patients who, in the opinion of the investigator, are unsuitable for mechanical thrombectomy as evidenced by imaging findings.",{"count":250,"type":20},360,[23],"To Evaluate the Safety and Efficacy of the Super-Bore 8\u002F7F Thrombosis Aspiration Catheter in the Treatment of Acute Intracranial Large Vessel Occlusion.",[26,254],"Endovascular Thrombectomy",[26,256,257],"Super-Bore 8F Thrombosis Aspiration Catheter","Acute Intracranial Large Vessel Occlusion","2024-12-14",{"date":260,"type":39},"2024-12-18",{"date":262,"type":20},"2024-12-16",{"date":264,"type":20},"2026-04-01",{"name":45,"class":46},{"id":267,"slug":268,"hasResults":11,"nctId":269,"briefTitle":270,"officialTitle":271,"acronym":4,"eligibilityCriteria":272,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":273,"targetDuration":4,"studyType":21,"phases":275,"briefSummary":276,"conditions":277,"keywords":278,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":282,"lastUpdatePostDateStruct":283,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":289,"locationsCount":74},"100559077","extending-the-time-window-for-intravenous-tenecteplase-in-patients-with-distal-medium-vessel-occlusions-stroke-100559077","NCT06559436","Extending the Time Window for Intravenous Tenecteplase in Patients With Distal Medium Vessel Occlusions Stroke","Extending the Time Window for Intravenous Tenecteplase in Patients With Distal Medium Vessel Occlusions Stroke-a Randomised, Controlled, Multicentre Study","Inclusion Criteria:\n\n1. Evidence of a primary (e.g., not secondary to endovascular therapy of proximal vessel occlusion) distal medium vascular occlusion defined as occlusion of the co\u002Fnon-dominant M2 segment\\*, M3, or M4 segment of the middle cerebral artery (MCA), the anterior cerebral artery (ACA) (A1, A2, A3, or A4 segments), or the posterior cerebral artery (PCA) (P1, P2, P3, or P4 segments);\n\n   \\* Co\u002Fnon-dominant M2 segment vessel diameter should not exceed 2.0 mm. Co-dominant supplying 50% of the MCA territory vs non-dominant supplying \\\u003C50% of the MCA territory.\n2. Age ≥18 years;\n3. Premorbid mRS 0-1;\n4. Evidence of a disabling stroke defined as follows:\n\n   1. Baseline National Institutes of Health Stroke Scale (NIHSS) score ≥4 at the time of randomization.\n   2. NIHSS 2-3 with disabling deficit including significant aphasia, neglect, hemianopsia, or hemiparesis\u002F loss of hand or leg function as established by the treating team in context of the patient's life.\n5. Less than 50% core in the territory supplied by the occluded vessel as evident by hypodensity and loss of grey-white border on NCCT or ADC \\\u003C620 mm2\u002Fs on diffusion MRI or rCBF\\\u003C30% on CTP after 6h of symptom onset.\n6. Time from onset (or time last seen well) to treatment within 4.5-24 hours;\n7. Informed consent obtained from patient or acceptable patient surrogate.\n\nExclusion Criteria:\n\n1. Received intravenous thrombolysis prior to randomization;\n2. Allergy to Tenecteplase;\n3. Seizures, or other neurological\u002Fmental illness at stroke onset if it precludes obtaining an accurate baseline NIHSS;\n4. Patients planned to undergo MT or other endovascular treatments (e.g., intra-arterial thrombolysis);\n5. Systolic blood pressure\\>185 mmHg or diastolic blood pressure\\>110 mmHg, which cannot be controlled by antihypertensive drug(s);\n6. Acute intracerebral hemorrhage identified by CT or MRI;\n7. Clinical presentation suggests a subarachnoid hemorrhage, even if initial CT or MRI scan is normal;\n8. Subjects with occlusions in multiple vascular territories (e.g., bilateral or multi-territorial anterior circulation, or anterior\u002Fposterior circulation);\n9. Contraindication to imaging with MR or CT with contrast agents;\n10. Known genetic or acquired bleeding diathesis, or received warfarin and INR \\> 1.7; or treated with direct oral anticoagulant agents in the prior 48 hours;\n11. Platelets \\\u003C100×109\u002FL, APTT \\> 40 s, or PT \\>15 s; Blood glucose \\\u003C50 mg\u002Fdl (2.7 mmol\u002FL) or \\>400 mg\u002Fdl (22.2 mmol\u002FL);\n12. Severe renal failure, defined as serum creatinine \\> 3.0 mg\u002Fdl (or 265.2 μmol\u002Fl) or glomerular filtration rate (GFR) \\\u003C 30, or patients requiring hemodialysis or peritoneal dialysis;\n13. Active internal hemorrhage or at high risk of bleeding, e.g., major surgery, sever trauma or gastrointestinal or urinary tract hemorrhage within the last 2 weeks, or arterial puncture at a non-compressible site within the previous 7 days;\n14. Ischemic stroke or myocardial infarction in previous 3 months, previous intracranial hemorrhage, severe traumatic brain injury or intracranial or intraspinal operation in previous 3 months, or known intracranial neoplasm, arteriovenous malformation or giant aneurysm;\n15. Life expectancy \\\u003C 1 year;\n16. Patients who cannot adhere to the trial protocol or follow-up;\n17. Currently participating in other clinical trials;\n18. Pregnant or lactating women;\n19. Any other condition that, in the opinion of the investigator, could impose hazards to the patient if study therapy is initiated or affect the participation of the patient in the study.",{"count":274,"type":20},560,[23],"To assess the safety and efficacy of beyond time window TNK intravenous thrombolysis for distal Medium Vessel Occlusion (MeVO) related stroke in a prospective randomized clinical trial.",[26],[279,280,64,281],"Medium Vessel Occlusion","Stroke Due To Medium Vessel Occlusion","TNK intravenous thrombolysis","2024-10-22",{"date":284,"type":39},"2024-10-24",{"date":286,"type":39},"2024-10-02",{"date":288,"type":20},"2026-12-01",{"name":45,"class":46},{"id":291,"slug":292,"hasResults":11,"nctId":293,"briefTitle":294,"officialTitle":295,"acronym":4,"eligibilityCriteria":296,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":297,"targetDuration":4,"studyType":21,"phases":299,"briefSummary":300,"conditions":301,"keywords":302,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":305,"lastUpdatePostDateStruct":306,"startDateStruct":308,"completionDateStruct":310,"leadSponsor":312,"locationsCount":74},"100527363","evaluation-of-endovascular-treatment-in-acute-intracranial-distal-medium-vessel-occlusion-stroke-100527363","NCT06146790","Evaluation of Endovascular Treatment in Acute Intracranial Distal Medium Vessel Occlusion Stroke","Evaluation of Endovascular Treatment in Acute Intracranial Distal Medium Vessel Occlusion Stroke - a Multicenter, Randomized Controlled, Clinical Trial","Inclusion Criteria:\n\n1. Age ≥18 years (no upper age limit).\n2. Evidence of a primary (e.g., not secondary to EVT of proximal vessel occlusion) distal medium vascular occlusion defined as occlusion of the co\u002Fnon-dominant M2 segment\\* or M3 segment of the MCA, the ACA (A1, A2, or A3 segments), or the PCA (P1, P2 or P3 segments) resulting in significant clinical deficits and expected to be treatable by endovascular thrombectomy.\n\n   \\* Co\u002Fnon-dominant M2 segment vessel diameter should not exceed 2.0 mm. Co-dominant supplying 50% of the MCA territory vs non-dominant supplying \\\u003C50% of the MCA territory.\n3. Premorbid mRS ≤ 2.\n4. Baseline National Institutes of Health Stroke Scale (NIHSS) score ≥6 at the time of randomization.\n5. Time from onset (or time last seen well) to randomization\\\u003C24 hours.\n6. For patients with more than 6 hours of onset (or time last seen well), Clinical-Imaging mismatch assessment defined as any of the following scenarios (A or B):\n\n   A. Non-contrast CT of the head or Brain MRI DWI lesion with \\\u003C50% involvement of the vascular territory corresponding to the clinical manifestation:\n\n   B. Target Mismatch Profile on CT perfusion or MRI (Mismatch Volume \\>10cc and mismatch Ratio \\>1.4 ).\n7. Informed consent obtained from patient or acceptable patient surrogate.\n\nExclusion Criteria:\n\n1. Any sign of intracranial hemorrhage on baseline CT\u002FMR (SDH\u002FSAH\u002FICH).\n2. Rapidly improving symptoms, particularly if in the judgment of the managing clinician that the improvement is likely to result in the patient having an NIHSS score of \\\u003C6 at randomization.\n3. Significant ischemic changes in a territory other than the occluded site that in the opinion of the investigator could reduce the benefit of endovascular treatment.\n4. Contra indication to imaging with MR or CT with contrast agents.\n5. Any terminal illness such that patient would not be expected to survive more than 1 year.\n6. Recent past history or clinical presentation of ICH, subarachnoid hemorrhage (SAH), arterio-venous (AV) malformation, aneurysm, or cerebral neoplasm other than meningioma.\n7. Any imaging findings suggestive of futile recanalization in the judgment of the local investigator.\n8. seizures at stroke onset if it precludes obtaining an accurate baseline NIHSS.\n9. Baseline blood glucose of \\\u003C50 mg\u002FdL (2.78 mmol) or \\>400 mg\u002FdL (22.20 mmol).\n10. Known history of hereditary or acquired hemorrhagic diathesis and\u002For platelet count \\\u003C50×109\u002FL.\n11. Known renal failure as defined as serum creatinine levels \\> 260umol\u002Fl（3.0 mg\u002FdL）.\n12. Presumed septic embolus or suspicion of bacterial endocarditis.\n13. Any other condition that, in the opinion of the investigator could impose hazards to the patient or affect the participation of the patient in the study if an endovascular procedure was performed.\n14. History of drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements.\n15. Subjects with occlusions in multiple vascular territories (e.g., bilateral or multi-territorial anterior circulation, or anterior\u002Fposterior circulation)\n16. Subject participating in a study involving an investigational drug or device that would impact this study.\n17. Known pregnancy.\n18. Prisoner or incarceration",{"count":298,"type":20},564,[23],"Rationale: Distal Medium Vessel Occlusion (MeVO) are thought to cause as many as 25% to 40% of all acute ischemic strokes (AIS). Despite their relatively high frequency, there is no consensus regarding the optimal management of these patients. However, the fact that AIS related to MeVO often results in significant disability despite best medical treatment (including intravenous thrombolysis, IVT) calls for novel treatment approaches. Fortunately, a growing number of non-randomized studies have now been published demonstrating the feasibility of endovascular treatment (EVT) for MeVO strokes. These studies have demonstrated that distal EVT leads to high rates of successful reperfusion and may be performed with a comparable safety profile to that of EVT for proximal arterial occlusions. Therefore, a strong rational exists to test the safety and efficacy of EVT for MeVO stokes in a prospective randomized clinical trial.\n\nObjectives: The primary objective of this study is to evaluate the hypothesis that endovascular thrombectomy is superior to standard medical management in achieving more favorable outcomes according to the modified Rankin Scale scores at 90 days in subjects presenting with acute ischemic stroke related to a distal medium vessel occlusion within 24 hours from symptom onset (defined as time last know well, TLKW).\n\nSecondary objectives include the assessment of the cost-effectiveness of endovascular thrombectomy in the medium vessel occlusion (MeVO) population as well as its impact on health-related quality of life.\n\nStudy design: The study is a prospective, multicenter, investigational, randomized, controlled, open-label study with blinded endpoint evaluation (PROBE design) and an adaptive design with population enrichment.\n\nStudy population: Subjects presenting with acute ischemic stroke within 24 hours from TLKW and whose strokes are attributable to a distal medium vascular occlusion defined as co\u002Fnon-dominant M2 segment or M3 segment of the MCA, the ACA (A1, A2, or A3 segments), or the PCA (P1, P2 or P3 segments) with evidence of salvageable brain tissue on perfusion imaging, M2 segment vessel diameter should not exceed 2.0 mm.\n\nPrimary outcome: Shift in distribution of all levels of the 90-day the modified Rankin Scale with levels 5-6 combined (mRS; 0, 1, 2, 3, 4, 5-6) as assessed by structured assessment.",[26,254],[279,280,303,304],"Endovascular Treatment","Standard Medical Management","2024-08-31",{"date":307,"type":39},"2024-09-05",{"date":309,"type":39},"2023-12-14",{"date":311,"type":20},"2026-03-01",{"name":45,"class":46},{"id":314,"slug":315,"hasResults":11,"nctId":316,"briefTitle":317,"officialTitle":318,"acronym":4,"eligibilityCriteria":319,"healthyVolunteers":11,"sex":16,"minAge":320,"maxAge":321,"enrollmentInfo":322,"targetDuration":4,"studyType":21,"phases":324,"briefSummary":325,"conditions":326,"keywords":330,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":333,"lastUpdatePostDateStruct":334,"startDateStruct":336,"completionDateStruct":338,"leadSponsor":339,"locationsCount":74},"100539472","a-study-assessing-the-effects-of-acupuncture-in-parkinsons-disease-patients-with-chronic-appendicitis-100539472","NCT06304285","A Study Assessing the Effects of Acupuncture in Parkinson's Disease Patients With Chronic Appendicitis","A Study Assessing the Effects of Acupuncture in Parkinson's Disease Patients With Chronic Appendicitis: a Single-center, Randomized, Double-blind Study","Inclusion Criteria:\n\n* Patients presenting with bradykinesia, combined with resting tremor and\u002For myotonia.\n* Appendix CT suggested chronic appendicitis evaluated by two experienced experts.\n* All subjects and their guardians give informed consent to the content of this study and sign informed consent.\n* Normal coagulation function.\n* If the patient had taken oral anti-PD drugs, it had been stable for at least 2 weeks at enrollment.\n\nExclusion Criteria:\n\n* Treatment with dopamine blockers or dopamine depleters in doses and time courses consistent with drug-induced parkinsonism.\n* Neuroimaging examination of presynaptic dopaminergic system function was normal.\n* Patients who had suffered severe brain trauma or underwent complex craniotomy within 5 years prior to enrollment.\n* Cognitive disorders that are not on the Parkinson's spectrum, such as Alzheimer's disease, frontotemporal dementia, and Niemann-Pick disease, have been diagnosed.\n* People diagnosed with severe neuropsychiatric disorders (epilepsy, bipolar disorder, major depressive episode, etc.) according to DSM-V.\n* Complicated with serious systemic diseases, disorders of consciousness, stroke, serious coronary heart disease, diabetes, liver and kidney diseases, and serious visual and hearing disorders.\n* Patients with severe organic or functional dysphagia;Those who were deemed by the researcher to be unable to complete the visit and auxiliary examination as required by the study protocol.","40 Years","70 Years",{"count":323,"type":20},84,[23],"The incidence of PD is high, and when the disease is serious to a certain extent, the effect of drugs to control symptoms decreases, resulting in a significant reduction in the quality of life of patients. Recent studies have found that these PD symptoms are closely related to the intestine. For several cases of PD syndrome patients complicated with chronic appendicitis, our research group conducted acupuncture on points related to constipation and chronic appendicitis, and found that constipation and related motor symptoms of patients could be significantly improved. Clinical studies have shown that acupuncture also has a certain therapeutic effect on non-motor symptoms of Parkinson's disease, such as anxiety and depression, decreased olfactory function, sleep disorders, constipation, early skeletal muscle pain, cognitive dysfunction, etc., which can delay the progression of the disease and improve the quality of life of patients. Starting from intestinal acupuncture, this project further clarified the role of acupuncture treatment in the comprehensive treatment of PD",[327,328,329],"Parkinson's Disease","Chronic Appendicitis","Acupuncture",[331,332],"Parkinson's disease","acupuncture","2024-03-04",{"date":335,"type":39},"2024-03-12",{"date":337,"type":20},"2024-03-01",{"date":223,"type":20},{"name":45,"class":46},""]